# A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

> **NCT07552077** · PHASE2 · RECRUITING · sponsor: **Palvella Therapeutics, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Angiokeratomas

## Interventions

- **DRUG:** PTX-022

## Key facts

- **NCT ID:** NCT07552077
- **Lead sponsor:** Palvella Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-08
- **Final completion:** 2027-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07552077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07552077, "A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07552077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*